MedTrace Logo

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

NCT06820268 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-03-04

No results posted yet for this study

Summary

Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies

Conditions

Interventions

DRUG

XS-04 tablet

Each treatment cycle is 28 days, with continuous oral administration, twice daily.

Sponsors & Collaborators

  • NovaOnco Therapeutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-14
Primary Completion
2027-11-01
Completion
2028-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06820268 on ClinicalTrials.gov